InvestorsHub Logo
Followers 54
Posts 3476
Boards Moderated 0
Alias Born 10/26/2013

Re: None

Thursday, 03/10/2022 7:27:19 AM

Thursday, March 10, 2022 7:27:19 AM

Post# of 3283
Hanmi cash infusion, JT leaving, Hanmi's Juhyun Lim added to the BOD - all directly related. And I believe a strong positive since she'll have some clout.

Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors
March 10 2022 - 07:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.
“We are delighted to have Ms. Lim join Spectrum’s Board of Directors,” said William Ashton, Chairman of the Board, Spectrum Pharmaceuticals. “This further strengthens our partnership with Hanmi and we look forward to her thoughtful guidance as we strategically define the next chapter at Spectrum and strive to advance novel medicines toward registration and commercialization.”
Juhyun Lim is an experienced executive with 20 years of experience in the life science industry and currently serves as President, Global Strategy and Planning at Hanmi Science and Hanmi Pharmaceutical, where she leads the execution of corporate strategy and investment. She also serves as Director, Healthcare Investment at Hanmi Ventures. Ms. Lim has held various senior leadership roles during her tenure at Hanmi, including SVP, Human Resource Development.
“I believe in Spectrum's commitment to serving patients with great needs and its vision and efforts for developing innovative medicines,” said Ms. Lim. “With Rolontis and poziotinib under Spectrum's lead, I am confident that the best efforts are put into the programs anticipating a great success in the oncology market. It is with great honor that l join the board and serve for a mutual goal.”

https://ih.advfn.com/stock-market/NASDAQ/spectrum-pharmaceuticals-SPPI/stock-news/87514240/spectrum-pharmaceuticals-appoints-juhyun-lim-of-ha